阿罗格尘螨疫苗治疗101例过敏性哮喘的疗效及安全性分析  

Efficacy and Safety of Novo-Helisen-Depot(NHD)observed among 101 patients with allergic asthma

作　　者：柴若楠[1] 林小平[1] 

机构地区：[1]沈阳军区总医院全军呼吸及过敏反应诊治中心,沈阳110016

出　　处：《中国中西医结合耳鼻咽喉科杂志》2012年第2期97-99,115,共4页Chinese Journal of Otorhinolaryngology in Integrative Medicine

摘　　要：目的观察阿罗格尘螨疫苗治疗过敏性哮喘的疗效及安全性。方法 101例尘螨过敏性哮喘患者,比较免疫治疗前及接受治疗后3年时的病情变化,总结疗效,分析免疫治疗过程中的局部和全身不良反应。结果治疗后患者的症状评分等多项指标均比治疗前有显著改善(P<0.05),应急用药量较治疗前明显减少(P<0.05)。治疗期间未发生严重不良事件。结论阿罗格免疫疗法是一种安全、有效的治疗方法。Objectives To evaluate the therapeutic effect of Novo-Helisen-Depot on the treatment of allergic asthma and its safety based on a clinical trial. Methods Included in this study were 101 cases with allergic asthma, sensitive to dust mates, treated by the immunotherapy of Novo-Helisen-Depot for 3 years. Then, a comparison on their therapeutic effect and the side effects either locally or systematically were made before and after the therapy. Results Significantly improved systemic scoring and some other indicators such as： the maximum ventilating volume and so on were observed by the end of therapeutic course lasted for 3 years （P〈0.05）, with obviously reduced need of the amount of symptoms controlling drugs for emergency treatment to the lesion attacking （P〈0.05）. During the whole therapeutic course, there were no serious adverse events happened to these cases. Conclusions This kind of immune therapy against dust mites are extremely effective and safe to treat allergic asthma induced by such antigens, thus it is worth to be promoted to practical use in clinic.

关 键 词：过敏性哮喘 脱敏疗法 疗效 安全性 

分 类 号：R562.25[医药卫生—呼吸系统]